Related Experiment Video

Updated: Aug 9, 2026

Coronary Progenitor Cells and Soluble Biomarkers in Cardiovascular Prognosis after Coronary Angioplasty
10:03

Coronary Progenitor Cells and Soluble Biomarkers in Cardiovascular Prognosis after Coronary Angioplasty

Published on: January 28, 2020

Prognostic values of soluble CD30 and CD30 gene polymorphisms in heart transplantation

Elisa Frisaldi1, Raffaele Conca, Paola Magistroni

  • 1Department of Genetics, Biology and Biochemistry, University of Turin, Turin, Italy.

Transplantation
|April 28, 2006
PubMed

Insights

Pretransplant soluble CD30 (sCD30) levels predict heart transplant (HT) patient survival. Lower pretransplant sCD30 levels are associated with significantly better outcomes in heart transplant recipients.

Area of Science:

  • Immunology
  • Transplantation Medicine
  • Genetics

Background:

  • Pretransplant soluble CD30 (sCD30) is a known predictor of kidney graft outcomes.
  • The predictive value of sCD30 for heart transplant (HT) outcomes remains unestablished.
  • The CD30 promoter microsatellite ((CCAT)n repeats) can influence gene transcription.

Purpose of the Study:

  • To investigate the role of pretransplant soluble CD30 (sCD30) levels as a predictor of heart transplant (HT) outcomes.
  • To explore the association between CD30 microsatellite (CCAT)n repeats and sCD30 levels in HT patients and donors.

Main Methods:

  • Assessed serum sCD30 levels in 83 HT patients and 77 donors.
  • Analyzed the number of (CCAT)n repeats in the CD30 promoter region.
  • Correlated sCD30 levels and microsatellite variations with patient survival post-transplantation.

Main Results:

  • Soluble CD30 (sCD30) levels were non-significantly increased in HT patients compared to controls.
  • No significant differences were observed in CD30 microsatellite allele frequencies between patients and donors.
  • A negative correlation was found between (CCAT)n repeat number and sCD30 levels in donors.
  • Patients with pretransplant sCD30 levels ≤30 U/ml demonstrated significantly improved survival rates.

Conclusions:

  • Pretransplant soluble CD30 (sCD30) levels are a significant predictor of heart transplant (HT) patient survival.
  • sCD30 serves as a valuable biomarker for assessing prognosis after heart transplantation.

More Related Videos

In Vitro and In Vivo Assessment of T, B and Myeloid Cells Suppressive Activity and Humoral Responses from Transplant Recipients18:48

In Vitro and In Vivo Assessment of T, B and Myeloid Cells Suppressive Activity and Humoral Responses from Transplant Recipients

Published on: August 12, 2017

Related Concept Videos

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...